{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:57:18Z","timestamp":1768514238257,"version":"3.49.0"},"posted":{"date-parts":[[2024,8,30]]},"group-title":"Microbiology","reference-count":17,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Only three classes of antifungal drugs are currently in clinical use. Here, we report that derivatives of the malarial drug mefloquine have broad spectrum antifungal activity including difficult to treat molds and endemic fungi. Pharmacokinetic and efficacy studies of NSC-4377 indicate it penetrates the central nervous system and is active against\n                  <jats:italic>Candida auris<\/jats:italic>\n                  in vivo. These data strongly support the further development of mefloquine analogs as a potentially new class of antifungal molecules.\n                <\/jats:p>","DOI":"10.1101\/2024.08.29.610379","type":"posted-content","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T22:05:12Z","timestamp":1725055512000},"source":"Crossref","is-referenced-by-count":0,"title":["Analogues of the anti-malaria drug mefloquine have broad spectrum antifungal activity and are efficacious in a model of disseminated\n                  <i>Candida auris<\/i>\n                  infection"],"prefix":"10.64898","author":[{"given":"Soumitra","family":"Guin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marhiah C.","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-1500","authenticated-orcid":false,"given":"Robert","family":"Zarnowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9950","authenticated-orcid":false,"given":"David R.","family":"Andes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin J.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle S.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-3365","authenticated-orcid":false,"given":"Damian J.","family":"Krysan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024090211101272000_2024.08.29.610379v1.1","doi-asserted-by":"crossref","first-page":"ofae363","DOI":"10.1093\/ofid\/ofae363","article-title":"Clinical mycology today: emerging challenges and opportunities","volume":"11","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2024090211101272000_2024.08.29.610379v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.46"},{"key":"2024090211101272000_2024.08.29.610379v1.3","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(20)30090-2","article-title":"Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations","volume":"1","year":"2020","journal-title":"Lancet Microbe"},{"key":"2024090211101272000_2024.08.29.610379v1.4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/jof7100804","article-title":"Augmenting the activity of chlorhexidine for decolonization of Candida auris from porcine skin","volume":"7","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024090211101272000_2024.08.29.610379v1.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2024.03.031","article-title":"Drug repurposing for bacterial infections","volume":"207","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2024090211101272000_2024.08.29.610379v1.6","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.drudis.2022.04.021","article-title":"Repurposing and optimization of drugs for discovery of novel antifungals","volume":"27","year":"2022","journal-title":"Drug Discov Today"},{"key":"2024090211101272000_2024.08.29.610379v1.7","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00765-13"},{"key":"2024090211101272000_2024.08.29.610379v1.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00212-12"},{"key":"2024090211101272000_2024.08.29.610379v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(19)30127-6"},{"key":"2024090211101272000_2024.08.29.610379v1.10","doi-asserted-by":"crossref","first-page":"e68929","DOI":"10.7554\/eLife.68929","article-title":"An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis","volume":"10","year":"2021","journal-title":"Elife"},{"key":"2024090211101272000_2024.08.29.610379v1.11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acsinfecdis.7b00157","article-title":"Antifungal phenothiazines: optimization, characterization of mechanisms, and modulation of neuroreceptor activity","volume":"4","year":"2018","journal-title":"ACS Infect Dis"},{"key":"2024090211101272000_2024.08.29.610379v1.12","first-page":"e02331","article-title":"Derivatives of the antimalarial drug mefloquine are broad-spectrum antifungal molecules with activity against drug-resistant clinical isolates","volume":"64","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024090211101272000_2024.08.29.610379v1.13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1021\/acsmedchemlett.4c00031","article-title":"Synthesis and antifungal activity of stereoisomers of mefloquine analogs","volume":"15","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"2024090211101272000_2024.08.29.610379v1.14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1021\/acsinfecdis.9b00478","article-title":"Benzothiourea derivatives target the secretory pathway of the human fungal pathogen Cryptococcus neoformans","volume":"6","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2024090211101272000_2024.08.29.610379v1.15","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-150"},{"key":"2024090211101272000_2024.08.29.610379v1.16","doi-asserted-by":"crossref","unstructured":"Dao A , Kim HY , Garnham K , Kidd S , Sati H , Perfect J , Sorrell TC , Harrison T , Rickerts V , Gigante V , Alastruey-Izquierdo A , Alffenaar JW , Morrissey CO , Chen SC , Beardsley J. 2024. Cryptococcosis-a systematic review to inform the World Health Organization fungal priority list. Med Mycol. 62: myae043.","DOI":"10.1093\/mmy\/myae043"},{"key":"2024090211101272000_2024.08.29.610379v1.17","first-page":"e00791","article-title":"Pharmacodynamic optimization for treatment of invasive Candida auris infection","volume":"61","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.08.29.610379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:57:56Z","timestamp":1768460276000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.08.29.610379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1101\/2024.08.29.610379","relation":{},"subject":[],"published":{"date-parts":[[2024,8,30]]},"subtype":"preprint"}}